Cite
MLA Citation
D Moro-Sibilot et al.. “Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.” Annals of oncology, vol. 30, 2019, pp. 1985–1991. http://access.bl.uk/ark:/81055/vdc_100098454627.0x000029
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
D Moro-Sibilot et al.. “Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.” Annals of oncology, vol. 30, 2019, pp. 1985–1991. http://access.bl.uk/ark:/81055/vdc_100098454627.0x000029